American Cyanamid of Wayne, N.J., named Albert Costellochairman and chief executive officer. Costello is currently thecompany's president, and is replacing George Sella, who isretiring at the end of March. Frank Atlee, currently anexecutive vice president, will succeed Costello as president.
BioCryst Pharmaceuticals Inc. of Birmingham, Ala., elected to itsboard of directors Randolph Steer, a consultant to thepharmaceutical and biotechnology industry who was chairman,president and chief executive officer of Advanced TherapeuticsCommunications International.
BTX Inc. of San Diego appointed to its scientific advisory boardMotonori Okino, chief of surgery at Mitajiri Hospital inYamaguchi, Japan.
CV Therapeutics of Mountain View, Calif., appointed GeorgeSchreiner vice president of medical science. Schreiner wasassociate professor of medicine and pathology at WashingtonUniversity School of Medicine.
Oncogene Science Inc. of Uniondale, N.Y., promoted ColinGoddard to director, pharmaceutical operations, from director,drug discovery. Also, Sara McKenzie was promoted to directorof clinical diagnostics from director of clinical development.
Pharmaceutical Proteins Ltd. of Edinburgh, Scotland, appointedAlan Colman full-time research director and Richard Crusefinance director. Colman was a professor in the department ofbiochemistry at the University of Birmingham. Cruse wasdirector of finance at Delta Biotechnology Ltd.
Protein Polymer Technologies Inc. of San Diego appointedBertram Rowland to its board of directors. Rowland has beenpatent attorney for a number of landmark patents inbiotechnology, including the Cohen-Boyer, Stanford-Universityof California patent on chimeric patents. He is currently withthe firm of Flehr, Hohbach, Test, Albritton & Herbert in PaloAlto, Calif.
Ribozyme Pharmaceuticals Inc. of Boulder, Colo., named J.Joseph Marr vice president, research and development, andchief scientific officer. Marr was vice president, discoveryresearch, at Searle Pharmaceuticals.
Shaman Pharmaceuticals Inc. of San Carlos, Calif., appointedMichel Bergh vice president, business development. Bergh wasdirector of business development in biotechnology at Schering,an operating unit of Schering-Plough.
(c) 1997 American Health Consultants. All rights reserved.